drugset / Trial / NCT07346196
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
Timeline
- Start
- 2027-02-07
- Primary completion
- 2031-08-22
- Completion
- 2031-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Fianlimab | Monoclonal antibody | 1600 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |